Last week the Filipino Department of Health ordered Sanofi to pull the vaccine off the market after the drugmaker released a report disclosing that the vaccine, Dengvaxia, may increase the risk of infection and worsen the symptoms of dengue in the long-term for people who were not exposed to the virus prior to vaccination.
A large majority of Dengvaxia’s sales have come from the Philippines through its government immunization program, which has vaccinated roughly 830,000 children.
“We will demand the refund of the 3 billion [pesos] paid for the Dengvaxia and will [demand] that Sanofi set up an indemnification fund to cover the hospitalization and medical treatment of all children who might have severe dengue,” The Philippines’ Health Secretary Francisco Duque told Reuters.
More articles on supply chain:
Prescription drug spending slows in 2016: 5 things to know
Worsening IV fluid shortage forces New York hospital to transfer patient
FDA urges drugmaker to recall osteoarthritis product following liver and lung injury reports
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
